The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study (NCT05321147) investigating lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). This agent attracts NK cells to attack cancer cells, and models have shown a synergistic effect when combined with chemotherapy regimens such as CHOP or bendamustine. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Salarius, Acrotech, CRISPR, Seagen, Yingli; Research Funding: Pfizer, Ono, Astra Zeneca, Legend, Acrotech, Innate, CRISPR, Seagen, Merck, Drenbio, Yingli; Speakers Bureau: CuraBio, American Society of Hematology, American Society of Transplant and Cellular Therapy.
